Double-Blind, Placebo-Controlled, Multiple-Ascending-Dose Study on the Pharmacodynamics of ABIO-08/01, a New CNS Drug with Potential Anxiolytic Activity

In a double-blind, placebo-controlled, multiple-ascending-dose study, the encephalotropic and psychotropic properties of ABIO-08/01, a new potentially anxiolytic and nootropic isoxazoline, were studied in 16 young healthy males. In a randomized nonbalanced phase 1 study, they received 3 oral drug doses (10, 20, 40 mg) and placebo for 7 days (washout period 8 days). EEG mapping and psychometry were carried out at hours 0, 1, 6 of day 1 (acute effect) and day 5 (subacute and superimposed effects). MANOVA/ Hotelling T2 test demonstrated significant central effects of ABIO-08/01 versus placebo after acute, subacute and superimposed administration of all doses in the resting, vigilance-controlled and eyes-open EEG. Univariate analysis revealed activating patterns in the resting EEG (40 mg > 20 mg > 10 mg), and sedative patterns in the eyes-open EEG (10 mg > 20 mg > 40 mg). In the vigilance-controlled EEG, 40 mg of ABIO-08/01 induced activating patterns, whereas 10 mg induced sedative patterns. Concerning psychometry, ABIO-08/01 improved concentration (40 mg > 20 mg > 10 mg; activating effect) and deteriorated well-being (10 mg > 20 mg > 40 mg; sedative effect). Ten milligrams also improved reaction time performance and psychomotor activity. ABIO-08/01 is well-tolerated and is of interest in anxiety disorders.

[1]  R. Swinson,et al.  Evaluation of Buspirone as an Antianxiety Agent: Buspirone and Diazepam versus Placebo* , 1989, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[2]  T. Gasser,et al.  Transformations towards the normal distribution of broad band spectral parameters of the EEG. , 1982, Electroencephalography and clinical neurophysiology.

[3]  M. Fredrikson,et al.  Cerebral blood flow during anxiety provocation. , 1997, The Journal of clinical psychiatry.

[4]  M. Buchsbaum,et al.  Topographic EEG changes with benzodiazepine administration in generalized anxiety disorder , 1985, Biological Psychiatry.

[5]  W M Herrmann,et al.  Reflections on the topics: EEG frequency bands and regulation of vigilance. , 1979, Pharmakopsychiatrie, Neuro-Psychopharmakologie.

[6]  S. Galderisi,et al.  Multilead quantitative EEG profile of clozapine in resting and vigilance-controlled conditions , 1996, Psychiatry Research: Neuroimaging.

[7]  Edward M. Cross,et al.  Use of the Binomial Theorem in Interpreting Results of Multiple Tests of Significance , 1982 .

[8]  J. Cohn,et al.  A pooled, double-blind comparison of the effects of buspirone, diazepam and placebo in women with chronic anxiety. , 1989, Current medical research and opinion.

[9]  R. Dolan,et al.  A Functional Anatomy of Anticipatory Anxiety , 1999, NeuroImage.

[10]  D. Schutter,et al.  A left-prefrontal lateralized, sympathetic mechanism directs attention towards social threat in humans: evidence from repetitive transcranial magnetic stimulation , 2002, Neuroscience Letters.

[11]  H. Sackeim,et al.  Dorsolateral prefrontal cortical pathology in generalized anxiety disorder: a proton magnetic resonance spectroscopic imaging study. , 2004, The American journal of psychiatry.

[12]  K. Weisman,et al.  Buspirone and diazepam in anxiety: a controlled study. , 1982, The Journal of clinical psychiatry.

[13]  D. Robinson,et al.  A Double‐Blind Comparison of Buspirone, Clobazam, and Placebo in Patients with Anxiety Treated in a General Practice Setting , 1990, Journal of clinical psychopharmacology.

[14]  K. Maurer,et al.  Topographic Brain Mapping of EEG and Evoked Potentials , 1989, Springer Berlin Heidelberg.

[15]  D. Wheatley.  Buspirone: multicenter efficacy study. , 1982, The Journal of clinical psychiatry.

[16]  J C Mazziotta,et al.  Automated labeling of the human brain: A preliminary report on the development and evaluation of a forward‐transform method , 1997, Human brain mapping.

[17]  J. Koivukangas,et al.  The effect of brain tumour laterality on anxiety levels among neurosurgical patients , 2003, Journal of neurology, neurosurgery, and psychiatry.

[18]  P. Anderer,et al.  Double‐blind, placebo‐controlled, multiple‐ascending‐dose study on the effects of ABIO‐08/01, a novel anxiolytic drug, on perception and cognition, utilizing event‐related potential mapping and low‐resolution brain electromagnetic tomography , 2008, Human psychopharmacology.

[19]  Bernd Saletu,et al.  EEG Topography and Tomography (LORETA) in the Classification and Evaluation of the Pharmacodynamics of Psychotropic Drugs , 2006, Clinical EEG and neuroscience.

[20]  B Saletu,et al.  Topographic brain mapping of EEG in neuropsychopharmacology--Part I. Methodological aspects. , 1987, Methods and findings in experimental and clinical pharmacology.

[21]  Nathaniel M. Alpert,et al.  The functional neuroanatomy of anxiety: a study of three disorders using positron emission tomography and symptom provocation , 1997, Biological Psychiatry.

[22]  J. P. Ary,et al.  Location of Sources of Evoked Scalp Potentials: Corrections for Skull and Scalp Thicknesses , 1981, IEEE Transactions on Biomedical Engineering.

[23]  Roberto D. Pascual-Marqui,et al.  EEG Mapping and Low-Resolution Brain Electromagnetic Tomography (LORETA) in Diagnosis and Therapy of Psychiatric Disorders: Evidence for a Key-Lock Principle , 2005, Clinical EEG and neuroscience.

[24]  P. Anderer,et al.  Comparative Placebo-controlled Pharmacodynamic Studies with Zotepine and Clozapine Utilizing Pharmaco-EEG and Psychometry , 1987, Pharmacopsychiatry.

[25]  J Grünberger,et al.  The effect of biologically-active light on the noo- and thymopsyche and on psychophysiological variables in healthy volunteers. , 1993, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[26]  R. Post,et al.  Regional brain activity during transient self-induced anxiety and anger in healthy adults , 1999, Biological Psychiatry.

[27]  Dietrich Lehmann,et al.  Space-oriented EEG segmentation reveals changes in brain electric field maps under the influence of a nootropic drug , 1993, Psychiatry Research: Neuroimaging.

[28]  K. K. Tan,et al.  The spatial location of EEG electrodes: locating the best-fitting sphere relative to cortical anatomy. , 1993, Electroencephalography and clinical neurophysiology.

[29]  Bernd Saletu,et al.  Artifact processing in topographic mapping of electroencephalographie activity in neuropsychopharmacology , 1992, Psychiatry Research: Neuroimaging.

[30]  Karl J. Friston,et al.  Comparing Functional (PET) Images: The Assessment of Significant Change , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  R D Pascual-Marqui,et al.  Classification and evaluation of the pharmacodynamics of psychotropic drugs by single-lead pharmaco-EEG, EEG mapping and tomography (LORETA). , 2002, Methods and findings in experimental and clinical pharmacology.

[32]  M. Schlund,et al.  Effects of citalopram on worry and brain activation in patients with generalized anxiety disorder , 2004, Psychiatry Research: Neuroimaging.

[33]  P. McGuire,et al.  Effects of Cannabidiol (CBD) on Regional Cerebral Blood Flow , 2004, Neuropsychopharmacology.

[34]  J. Talairach,et al.  Co-Planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging , 1988 .

[35]  R. Luthringer,et al.  Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs , 2007, Journal of psychopharmacology.

[36]  E. John,et al.  Neurometrics: computer-assisted differential diagnosis of brain dysfunctions. , 1988, Science.

[37]  D. Lehmann,et al.  Low resolution electromagnetic tomography: a new method for localizing electrical activity in the brain. , 1994, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[38]  T. Gasser,et al.  Test-retest reliability of spectral parameters of the EEG. , 1985, Electroencephalography and clinical neurophysiology.

[39]  T. Koenig,et al.  Low resolution brain electromagnetic tomography (LORETA) functional imaging in acute, neuroleptic-naive, first-episode, productive schizophrenia , 1999, Psychiatry Research: Neuroimaging.

[40]  L. Aftanas,et al.  Trait anxiety impact on posterior activation asymmetries at rest and during evoked negative emotions: EEG investigation. , 2005, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[41]  Roberto D. Pascual-Marqui,et al.  Effect of the 5-HT1A partial agonist buspirone on regional brain electrical activity in man: a functional neuroimaging study using low-resolution electromagnetic tomography (LORETA) , 2000, Psychiatry Research: Neuroimaging.

[42]  J Grünberger,et al.  Topographic brain mapping of EEG in neuropsychopharmacology--Part II. Clinical applications (pharmaco EEG imaging). , 1987, Methods and findings in experimental and clinical pharmacology.

[43]  F. Duffy,et al.  Significance probability mapping: an aid in the topographic analysis of brain electrical activity. , 1981, Electroencephalography and clinical neurophysiology.